Fluctuations of haemoglobinaemia in chronic haemodialysis patients

Acta Clinica Belgica

Volumn 66, Issue 2, 2011, Pages 123-128

  De Meester, J ^a   Maes, B ^b   De Vriese, A ^c   De Moor, B ^d   Donck, J ^c   Helbert, M ^c   Bammens, B ^e   Jamar, S ^f  

^a AZ Nikolaas   (Belgium)

^b Heilig Hart Ziekenhuis   (Belgium)

^c Universitair Ziekenhuis Leuven campus Gasthuisberg ^*  (Belgium)

^d Van Het Jessa Ziekenhuis   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f IMELDA HOSPITAL   (Belgium)

Author keywords

Erythropoietin; Haemodialysis; Haemoglobin fluctuation; Haemoglobinaemia; Iron

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; ARTICLE; COMORBIDITY; DISEASE ASSOCIATION; ERYTHROPOIESIS; GENERAL ASPECTS OF DISEASE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MEDICAL PRACTICE; METHEMOGLOBINEMIA; METHODOLOGY; NEPHROLOGIST; OUTCOME ASSESSMENT; STANDARD; ACUTE DISEASE; CHRONIC KIDNEY FAILURE; CONSENSUS; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; METABOLISM; MONITORING; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ACUTE DISEASE; ANEMIA; COMORBIDITY; CONSENSUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MONITORING, PHYSIOLOGIC; REFERENCE STANDARDS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 79960933711     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.2143/ACB.66.2.2062530     Document Type: Article

References (40)

1. Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 33-38.
2. Levin N. Management of blood pressure changes during recombinant human erythropoietin therapy. Semin Nephrol 1989; 9 (1 Suppl 2): 16-20. (Pubitemid 19159978)
3. Bunn HF. New agents that stimulate erythropoiesis. Blood 2007; 109: 868-876.
4. Uehlinger D, Gotch F, Sheiner L. A pharmacodynamic model of erythropoetin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76-89.
5. Gross AW, Lodish HF. Cellular trafficking and degradation of eyrthropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 2006; 281: 2024-2032. (Pubitemid 43845790)
6. Agoram B, Aoki K, Doshi S, et al. Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietin receptor-mediated pathways may play a major role. J Pharm Sci 2009; 98: 2198-2211.
7. Piron M, Loo M, Gothot A, Tassin F, Fillet G, Beguin Y. Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia. Blood 2001; 97: 422-448.
8. Milutinovic S, Trkulja V. Reduced responsiveness to epoietin at re-exposure after prolonged epoietin-free period in anemic hemodialysis patients with end-stage renal disease. Croat Med J 2006; 47: 424-432.
9. Locatelli F, Aljama P, Bárány P, et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 Suppl 2: ii1-47.
10. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease. N Engl J Med 2006; 355: 2071-2084. (Pubitemid 44749316)
11. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. (Pubitemid 44749317)
12. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. Am J Kidney Dis 2007; 50: 471-530.
13. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R; ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24: 348-354.
14. Pfeffer MA., Burdmann EA., Chen C. Et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
15. Brimble KS, Clase CM. Hemoglobin variability in dialysis patients. J Am Soc Nephrol 2007; 18: 2218-2220. (Pubitemid 47203834)
16. Kalantar-Zadeh K, AronoffGR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol 2009; 20: 479-487.
17. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 2004; 44: 94-111. (Pubitemid 38880932)
18. Ebben J, Gilbertson D, Foley R, Collins A. Hemoglobin level variability: associations with comorbidity, intercurrent events and hospitalizations. Clin J Am Soc Nephrol 2006; 1: 1205-1210.
19. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005; 46: 484-488.
20. Fishbane S, Berns JS. Evidence and implications of haemoglobin cycling in anaemia management. Nephrol Dial Transplant 2007; 22: 2129-2132. (Pubitemid 47244687)
21. Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003; 41: 111-124. (Pubitemid 36043358)
22. Arneson TJ, Zaun D, Peng Y, Solid CA, Dunning S, Gilbertson DT. Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population. Nephrol Dial Transplant 2009; 24: 1378-1383.
23. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18: 3164-3170. (Pubitemid 350223976)
24. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003; 63: 1908-1914. (Pubitemid 36513341)
25. Breiterman-White R. Infection and infl ammation in patients on dialysis: an underlying contributor to anemia and epoetin alfa hyporesponse. Nephrol Nurs J 2006; 33: 319-324.
26. Fihn SD, Gadisseur AA, Pasterkamp E, et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Tromb Haemost 2003; 90: 260-266. (Pubitemid 36992502)
27. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008; 3: 133-138.
28. Regidor DL, Kopple HD, Kovesdy EP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191.
29. Ishani A, Solid CA, Weinhandl ED, Gilberson DT, Foley RN, Collins AJ. Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant 2008; 23: 1682-1689. (Pubitemid 351767748)
30. Bradbury BD, Danese MD, Gleeson M, Critchlow CW. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL. Clin J Am Soc Nephrol 2009; 4: 630-637.
31. Iaina A, Silverberg DS, Wexler D. Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal syndrome. Nat Clin Pract Cardiovasc Med 2005; 2: 95-100. (Pubitemid 40778861)
32. Similowski T, Agusti A, MacNee W, Schönhofer B. The potential impact of anaemia of chronic disease in COPD. Eur Respir J 2006; 27: 390-396. (Pubitemid 43180920)
33. Douglas Rizzo J, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008; 111: 25-41.
34. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved haemoglobin outcomes. Kidney Int 2008; 74: 791-798.
35. Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083.
36. Besarab A, Goodkin DA, Nissenson AR. The normal haematocrit study - followup. N Engl J Med 2008; 358: 433-434.
37. Heung M, Müller BA, Segal JH. Optimizing anemia management in hospitalized patients with end-stage renal disease. Ann Pharmocother 2009; 43: 276-282.
38. Richardson D, Bartlett C, Will EJ. Intervention thresholds and ceilings can determine the haemoglobin outcome distribution in a haemodialysis population. Nephrol Dial Transplant 2000; 15: 2007-2013.
39. Gabutti L, Lötscher N, Bianda J, Marone C, Mombelli G, Burnier M. Would artifi- cial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness? BMC Nephrology 2006; 7: 13.
40. Will EJ, Richardson D, Tolman C, Bartlett C. Development and exploitation of a clinical decision support system for the management of renal anaemia. Nephrol Dial Transplant 2007; 22 [Suppl 4]: 31-36.